Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates.
- In 2023, Editas Medicine strengthened and focused its discovery organization to build an in vivo gene editing pipeline.
- Editas Medicine plans to participate in the following investor events:
The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. - ET to provide and discuss a corporate update and financial results for the fourth quarter and full year of 2023.